hotspot -WSS

hotspot

author：hotspot 2025-09-06 02:16:51 - browse：24357

Adam's take main illustration — Molly Ferguson/STAT

Cytokinetics was founded 26 years ago but has not yet developed a drug successfully to approval. That makes Tuesday’s Food and Drug Administration decision on its treatment for heart failure a big deal — except nearly everyone, even investors who own Cytokinetics — hopes the agency rules against it.

Hoping the FDA rejects the Cytokinetics drug, called omecamtiv mecarbil, is a relatively uncommon, up-is-down, down-is-up situation, but it makes sense in this case because the business and science of the drug are not aligned.

Consider: Cytokinetics shares rose in December when an outside group of experts convened by the FDA to examine omecamtiv’s benefits and risks recommended against the medicine’s approval. On Tuesday, the FDA is most likely to heed that advice and turn down the company’s marketing application.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： John Green on his newest strategy for fighting tuberculosis

WSS

Readout Newsletter: The latest on Moderna, Apellis, and Merck

SNAP should offer more nutrition education

HCA sued by state AG for quality issues at Mission Health

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

leisure time

hotspot

hotspot

Alkermes shareholders re

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Jerome Adams on the need for new antivirals for Covid

John Green on his newest strategy for fighting tuberculosis

Alkermes shareholders re

Amid AI frenzy, a top HHS official's quest to create safeguards

Hepatitis C has a cure — but many Americans still lack access to it

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Medicare details structure of new drug price negotiation program

John Green on his newest strategy for fighting tuberculosis

hotspot

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Steward Health Care Massachusetts hospitals face fiscal disaster

Keeping primary care docs in field isn't impossible, says AAFP CEO

President Biden's budget: Here's what you might have missed

Medicare coverage of Wegovy, once blocked, now looks possible

How many hemophilia patients actually want gene therapy?

leisure time

explore

hotspot

knowledge